PE20150198A1 - Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montana por falta de oxigeno y presion de aire reducida - Google Patents

Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montana por falta de oxigeno y presion de aire reducida

Info

Publication number
PE20150198A1
PE20150198A1 PE2014002486A PE2014002486A PE20150198A1 PE 20150198 A1 PE20150198 A1 PE 20150198A1 PE 2014002486 A PE2014002486 A PE 2014002486A PE 2014002486 A PE2014002486 A PE 2014002486A PE 20150198 A1 PE20150198 A1 PE 20150198A1
Authority
PE
Peru
Prior art keywords
montana
treatment
lack
oxygen
pharmaceutical composition
Prior art date
Application number
PE2014002486A
Other languages
English (en)
Spanish (es)
Inventor
Bernhard Fischer
Rudolf Lucas
Hendrik Fischer
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of PE20150198A1 publication Critical patent/PE20150198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PE2014002486A 2012-06-28 2013-06-19 Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montana por falta de oxigeno y presion de aire reducida PE20150198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12173983.3A EP2679239A1 (de) 2012-06-28 2012-06-28 Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit

Publications (1)

Publication Number Publication Date
PE20150198A1 true PE20150198A1 (es) 2015-02-19

Family

ID=48672620

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002486A PE20150198A1 (es) 2012-06-28 2013-06-19 Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montana por falta de oxigeno y presion de aire reducida

Country Status (14)

Country Link
US (2) US9802985B2 (enExample)
EP (2) EP2679239A1 (enExample)
JP (1) JP6113277B2 (enExample)
KR (1) KR102010793B1 (enExample)
CN (1) CN104427993B (enExample)
AP (1) AP2014008162A0 (enExample)
AU (1) AU2013283563B2 (enExample)
CA (1) CA2875749C (enExample)
EA (1) EA030384B1 (enExample)
ES (1) ES2602197T3 (enExample)
IN (1) IN2015DN00585A (enExample)
MX (1) MX354302B (enExample)
PE (1) PE20150198A1 (enExample)
WO (1) WO2014001177A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2791225T3 (es) * 2014-03-04 2020-11-03 Apeptico Forschung & Entwicklung Gmbh Atenuación de la inflamación intrapulmonar
WO2015140125A2 (en) * 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
EP3365275A4 (en) 2015-08-25 2019-06-26 Bar-Ilan University ASYMMETRIC ELECTROCHEMICAL CELL DEVICE AND METHOD OF OPERATING THE SAME
CA3063524A1 (en) 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
EP4051311A4 (en) * 2019-10-29 2023-12-06 University of Pittsburgh - of the Commonwealth System of Higher Education LUNG-SPECIFIC TARGETING PEPTIDE (LTP), COMPOSITIONS AND RELATED USES
CN115461356A (zh) 2020-05-08 2022-12-09 阿佩普蒂科研究和开发有限责任公司 用于预防或治疗covid-19的肽
KR20250164550A (ko) 2024-05-16 2025-11-25 장태현 고산병 예방을 위한 입술용 화장료 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
CA2155103A1 (en) 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
JP4542266B2 (ja) 1998-08-14 2010-09-08 ルドルフ・ルカス 浮腫の治療に使用されるｔｎｆ由来のペプチド
WO2006013183A1 (en) * 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
MX2011009251A (es) * 2009-03-04 2011-11-18 Mannkind Corp Sistema mejorado de suministro de farmaco en polvo seco.
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase

Also Published As

Publication number Publication date
EA030384B1 (ru) 2018-07-31
KR20150037815A (ko) 2015-04-08
EA201500061A1 (ru) 2015-06-30
CN104427993B (zh) 2017-03-08
US9802985B2 (en) 2017-10-31
ES2602197T3 (es) 2017-02-20
CA2875749A1 (en) 2014-01-03
AU2013283563B2 (en) 2017-06-08
JP2015526399A (ja) 2015-09-10
JP6113277B2 (ja) 2017-04-12
MX2014015048A (es) 2015-06-05
EP2866824B1 (de) 2016-08-10
KR102010793B1 (ko) 2019-08-14
US20150225460A1 (en) 2015-08-13
US20190211061A1 (en) 2019-07-11
WO2014001177A1 (de) 2014-01-03
CN104427993A (zh) 2015-03-18
AP2014008162A0 (en) 2014-12-31
IN2015DN00585A (enExample) 2015-06-26
EP2679239A1 (de) 2014-01-01
CA2875749C (en) 2019-02-26
MX354302B (es) 2018-02-23
AU2013283563A1 (en) 2015-01-15
EP2866824A1 (de) 2015-05-06

Similar Documents

Publication Publication Date Title
PE20150198A1 (es) Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montana por falta de oxigeno y presion de aire reducida
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
CL2016001405A1 (es) A peptide mixture
CL2011001498A1 (es) Profarmaco que comprende la estructura a-b-q donde q es un peptido de la superfamilia de glucagon, a es un aminoacido o un hidroxiacido y b es un aminoacido n-alquilado ligado a q; composicion farmaceutica que comprende el profarmaco; metodo para suprimir el apetito o inducir la perdida de peso.
PE20121393A1 (es) Analogo peptidico de oxintomodulina
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
MX2023001319A (es) Polipeptidos condicionalmente activos.
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
UA118167C2 (uk) Пептид та його застосування
CL2013001655A1 (es) Compuestos bifenilicos sustituidos; composicion farmaceutica; y uso en el tratamiento o prevencion de fibrosis pulmonar, renal, hepatica o cutanea.
CL2008003476A1 (es) Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
AR083366A1 (es) Formulaciones para el tratamiento de las afecciones de las vias aereas superiores
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
CL2019003407A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
MX2016002937A (es) Vacuna oncologica.
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
WO2014100481A8 (en) Modified alpha hemolysin polypeptides and methods of use
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
EA201490901A1 (ru) Линкеры на основе тирозина для свободного соединения пептидов
ES2506168T3 (es) Polipéptido que tiene actividad antibacteriana y actividad que induce la angiogénesis y fármacos que contienen dicho polipéptido que curan heridas
AR096273A1 (es) Composición para la higiene bucal con piedra pómez y carbonato de calcio

Legal Events

Date Code Title Description
FD Application declared void or lapsed